T2 Biosystems to Participate in the 2015 BIO International Convention
Members of the company's management are scheduled to participate in the following discussion panels:
Title: | Transforming Diagnostics With Innovative Technologies: Potential and Pitfalls |
Date & Time: | Wednesday, June 17, 2015, 2:00-3:15 p.m. EDT |
Session: | Breakout Session – Personalized Medicine & Diagnostics |
Location: | Room 105AB |
Moderator: | Jo Natauri, partner, Goldman Sachs |
Speakers: | John McDonough, president and CEO, T2 Biosystems |
Don Hardison, president and CEO, Good Start Genetics | |
Michael Pellini, M.D., CEO, Foundation Medicine | |
Title: | Circling the Wagons: Can Vaccines, Diagnostics, and Novel Products Make Antibiotics Better? |
Date & Time: | Thursday, June 18, 2015, 1:00-2:15 p.m. EDT |
Session: | Breakout Session – Infectious Diseases |
Location: | Room 113A |
Moderator: | Bruce Gellin, director, National Vaccine Program Office, HHS |
Speakers: | Tom Lowery, Ph.D., CSO, T2 Biosystems |
Tim Cooke, Ph.D., CEO, Novadigm | |
Charles Knirsch, M.D., MPH, vice president, Vaccines Clinical Research, Pfizer | |
Florence Sejourne, CEO, Da Volterra |
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the
CONTACT: Media Contact:Dan Budwick ,Pure Communications dan@purecommunicationsinc.com 973-271-6085 Investor Contact:Matt Clawson ,Pure Communications matt@purecommunicationsinc.com 949-370-8500